There are currently 523 clinical trials in Tucson, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Arizona, Banner University Medical Center - Tucson, Arizona Cancer Center and University of Arizona Cancer Center-North Campus. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
NCT05870748
Recruiting
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Arizona Oncology Associates, PC-Hope, Tucson, Arizona
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
Register for Updates
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
NCT05548283
Recruiting
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. Both doctors and CF patients are trying to understand the best way to treat pulmonary exacerbations. This study is trying to answer the following questions about treating a pulmonar... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
08/23/2024
Locations: Tucson Cystic Fibrosis Center, Tucson, Arizona
Conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Register for Updates
Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome
NCT05933603
Recruiting
This is an open-label study of the combination of atomoxetine and oxybutynin (ato-oxy) in children with Down syndrome and obstructive sleep apnea (OSA) documented by polysomnography (PSG). Participants will receive ato-oxy for 6 months. Ato-oxy dose will be 5 mg oxybutynin and 0.5mg/kg/day (max 40 mg) atomoxetine. Dosing of the study treatment will occur approximately 30 minutes prior to bedtime. Participants who withdraw from the study will not be replaced. Study participants will undergo elig... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/22/2024
Locations: University of Arizona, Tucson, Arizona
Conditions: Obstructive Sleep Apnea, Down Syndrome
Register for Updates
The Effect of Prior Learning on Treatment of Morpheme Errors
NCT05953077
Recruiting
This is a small-scale treatment study designed to determine which teaching methods result in the best learning. Treatment focuses on helping children with a developmental language disorder learn parts of grammar. Preschool children will receive assessments to determine whether they have a developmental language disorder and what parts of grammar they have not mastered. Children will receive one-on-one behavioral treatment over a six week period. Half of the children will be first taught a gramma... Read More
Gender:
ALL
Ages:
Between 4 years and 6 years
Trial Updated:
08/22/2024
Locations: University of Arizona, Tucson, Arizona
Conditions: Developmental Language Disorder
Register for Updates
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/21/2024
Locations: University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona +2 locations
Conditions: Multiple Myeloma
Register for Updates
CardioFocus HeartLight Post-Approval Study
NCT03168659
Recruiting
This is a post-approval study to evaluate the clinical outcomes in a cohort of participants treated during commercial use of the HeartLight System to confirm results of the previously conducted pivotal clinical study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2024
Locations: University of Arizona Sarver HeartCenter, Tucson, Arizona
Conditions: Atrial Fibrillation
Register for Updates
A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
NCT02491099
Recruiting
Primary Objective: To assess the activity of Afatinib in patients with persistent or recurrent uterine serous carcinoma overexpressing HER2/neu with the frequency of patients who survive progression-free for at least 6 months after initiating therapy. Secondary Objectives: To assess objective response rate and durable disease control rate. To assess overall survival. To assess the safety profile of Afatinib in uterine serous carcinoma patients.
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
08/16/2024
Locations: University of Arizona Cancer Center, Tucson, Arizona
Conditions: HER2/Neu+ Uterine Serous Carcinoma
Register for Updates
Arizona Alzheimer's Disease Research Center (ADRC)
NCT05405075
Recruiting
The Arizona Alzheimer's Disease Research Center (ADRC) is the National Institute on Aging's (NIA's) first statewide AD Center (ADC), the only ADC in the Southwestern United States, and a leading example of statewide collaboration in biomedical research. It capitalizes on Arizona's strengths in brain imaging, genomics, computer science and biomathematics, the basic, cognitive and behavioral neurosciences, clinical, and neuropathological studies of AD, the discovery and evaluation of investigation... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/16/2024
Locations: Banner Alzheimer's Institute - Tucson, Tucson, Arizona
Conditions: Alzheimer Disease
Register for Updates
Arizona Cancer Center Biospecimen Repository
NCT00896935
Recruiting
RATIONALE: Collecting and storing samples of tissue and blood from patients with cancer to test in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing tumor, tissue, and blood samples from patients with pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona
Conditions: Cancer
Register for Updates
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona +1 locations
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
NCT04510597
Recruiting
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Banner University Medical Center - Tucson, Tucson, Arizona +1 locations
Conditions: Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Register for Updates
Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS
NCT05938036
Recruiting
A Phase 2a, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of ALT-100mAb in patients with moderate to severe ARDS.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/14/2024
Locations: Banner University of Arizona, Tucson, Arizona
Conditions: Acute Respiratory Distress Syndrome (ARDS)
Register for Updates